20 December 2022: Original Paper
Potential Utility of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Neutrophil, Lymphocyte, and Platelet Ratios in Differential Diagnosis of Kidney Transplant Acute Rejection: A Retrospective, Propensity Score Matched Analysis
Aureliusz Kolonko 1ABCDEF* , Tomasz Dwulit 1BDE , Michał Skrzypek 2CDE , Andrzej Więcek 1EDOI: 10.12659/AOT.937239
Ann Transplant 2022; 27:e937239
Table 1 Clinical characteristics of study subgroups with and without early acute rejection episode in the early post-transplant period.
| Variable | Acute rejection n=71 | No rejection n=71 | Statistics |
|---|---|---|---|
| Recipients age [years] | 51.4 (48.5–54.4) | 51.7 (49.1–54.3) | 0.89 |
| Sex [M/F] | 37/34 | 39/32 | 0.74 |
| BMI [kg/m] | 26.0 (25.0–26.9) | 25.4 (24.5–26.4) | 0.43 |
| Dialysis vintage [months]* | 31 (22–63) | 29 (20–40) | 0.27 |
| Diabetes [n (%)] | 9 (12.7) | 13 (18.3) | 0.36 |
| Post-transplant observation time [months] | 46 (41–51) | 46 (41–51) | 0.89 |
| Last PRA >20% [n (%)] | 6 (8.6) | 6 (8.6) | 1.0 |
| Transplant No [1/2/3] | 53/15/3 | 56/14/1 | 0.57 |
| Donor age [years] | 47.6 (44.4–50.8) | 46.9 (43.9–49.9) | 0.77 |
| Donor serum creatinine >1.5 mg/dl [n (%)] | 24 (33.8) | 21 (29.6) | 0.59 |
| ECD status [n (%)] | 22 (31.9) | 20 (28.2) | 0.71 |
| CIT [h] | 18.1 (16.5–19.7) | 17.6 (15.9–19.3) | 0.69 |
| HLA class I mismatch | 2.3 (2.1–2.6) | 2.1 (1.9–2.3) | 0.22 |
| HLA class II mismatch | 0.73 (0.59–0.88) | 0.63 (0.49–0.77) | 0.33 |
| Induction therapy (ATG/IL-2RB/none) | 19/38/14 | 17/39/15 | 0.92 |
| Initial graft function (IGF/SGF/DGF) | 11/33/27 | 15/34/22 | 0.57 |
| Initial tacrolimus level [ng/ml] | 14.1 (12.3–16.0) | 13.2 (11.7–14.8) | 0.47 |
| Tacrolimus level at 7–9 POD [ng/ml] | 7.9 (7.3–8.4) | 8.4 (7.6–9.1) | 0.27 |
| Mycophenolate mofetil initial dose [g/day]* | 1.0 (1.0–1.5) | 1.0 (1.0–1.5) | 0.98 |
| Data presented as means with 95% confidence interval or * medians with Q25–Q75 quartile values or frequencies. BMI – body mass index; PRA – panel-reactive antibodies; HLA – human leukocyte antigen; MICA – human major histocompatibility complex class I-related gene A; ECD – extended criteria donor; CIT – cold ischemia time; ATG – antithymocyte globulin; IL-2RB – interleukin-2 receptor blocker; IGF – immediate graft function; SGF – slow graft function; DGF – delayed graft function; POD – post-operative day. | |||